Table 3.

Trials of adjuvant radiotherapy and chemotherapy in endometrial cancer

Trial	Enrollment	No. of patients	Eligibility	Randomization	5-Year overall survival	5-Year progression-free survival
Italian15	1990–1997	345	Stage I–II with grade 3 tumor; stage III	Pelvic RT vs 5 x CAP	69% vs 66% (NS)	63% vs 63% (NS)
GOG-12214	1992–2000	396	Stage III and IV, up to 2 cm residual disease after surgery allowed	Whole abdomen irradiation vs 8 x AP	42% vs 55% (p<0.01)	38% vs 50% (p<0.01)
Japanese16	1994–2000	385	Stage I–II with >50% myometrial invasion	Pelvic RT vs 3 x CAP	85% vs 87% (NS)	84% vs 82% (NS)
NSGO/EORTC pooled with Iliade-III17	1996–2007	534, NSGO/EORTC 378 and Iliade 156	NSGO/EORTC stage I–III; Iliade stage II–III	Pelvic RT vs pelvic RT and 4 x AP or TAP or TC or TEP	75% vs 82% (p=0.07)	69% vs 78% (p=0.02)
PORTEC-320	2006–2013	686	Stage I–II with high-risk factors, stage III	Pelvic RT vs pelvic RT with 2 x CP followed by 4 x TC	76% vs 81% (p=0.034) Stage III 69% vs 79% Serous EC 53% vs 71%	69% vs 77% (p=0.016) Stage III 58% vs 71% Serous EC 47% vs 60%
GOG-24918	2009–2013	601	Stage I–II with high-intermediate or high-risk factors	Pelvic RT vs VBT and 3 x TC	87% vs 85% (NS)	76% vs 76% (NS)
GOG-25821	2009–2014	736	Stage III and IVa without residual disease up to 2 cm	Pelvic RT with 2 x CP followed by 4 x TC vs 6 x TC	70% vs 73% (NS)	59% vs 58% (NS)

AP, doxorubicin plus cisplatin; CAP, cyclophosphamide, doxorubicin, and cisplatin; CP, cisplatin; EC, endometrial cancer; GOG, Gynaecologic Oncology Group; NS, not significant; NSGO/EORTC, Nordic Society of Gynecologic Oncology/European Organization for Research and Treatment of Cancer; PORTEC, Post Operative Radiation Therapy for Endometrial Carcinoma; RT, radiation therapy; TAP, doxorubicin, cisplatin, and paclitaxel; TC, paclitaxel plus carboplatin; TEP, paclitaxel, epirubicin, and cisplatin; VBT, vaginal brachytherapy.